Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shingrix (HZ/su) Safety and Immunogenicity in Adults 50+ (0,2 vs 0,6 vs 0,12 Month Schedules)
NCT01751165Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2013
- Primary completion
- May 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 3 trial of herpes zoster vaccine (recombinant, adjuvanted) in herpes zoster (HZ), sponsored by GSK. Started Mar 2013; status: completed.
02
Drugs
herpes zoster vaccine (recombinant, adjuvanted)
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT01751165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01751165.